

Malawi
Support for Injection Safety Devices

This Decision Letter sets out the Programme Terms of a Programme.

| | | | | | | |
|---|----------------|----------------|---------------|---------|--------|--------------------|
| 1. Country: Malawi | | | | | | |
| 2. Grant number: 17-MWI-32a-X / 18-MWI-32a-X / 19-MWI-32a-X / 20-MWI-32a-X / 21-MWI-32a-X | | | | | | |
| 3. Date of Decision Letter: 12 April 2018 | | | | | | |
| 4. Date of the Partnership Framework Agreement: 22 October 2014 | | | | | | |
| 5. Programme title: Injection safety devices ¹ | | | | | | |
| 6. Programme duration²: 2017-2021 | | | | | | |
| 7. Programme Budget (indicative): (subject to the terms of the partnership framework agreement, if applicable) | | | | | | |
| | 2017 | 2018 | 2019 | 2020 | 2021 | Total ³ |
| Programme Budget (US\$) | 273,706 | 126,000 | 275,500 | 387,000 | 22,500 | 1,084,706 |
| 8. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁴ | | | | | | |
| TOTAL injection safety devices to be purchased with Gavi funds in each year | 2017 | 2018 | 2019 | | | |
| Number of AD syringes | | 2,658,600 | 546,400 | | | |
| Number of re-constitution syringes | | 88,200 | | | | |
| Number of safety boxes | | 30,250 | 6,025 | | | |
| Annual Amounts for injection safety devices for all Gavi vaccines (US\$) | 273,706 | 126,000 | 25,000 | | | |

¹ This does not include vaccines.

² This is the entire duration of the Programme.

³ This is the total amount endorsed by Gavi for the entire duration of the Programme.

⁴ This is the amount that Gavi has approved.

Injection safety devices to be purchased with Gavi funds in each year, by type of support

| New Vaccine Support (NVS), Measles Rubella, 10 dose(s) per vial, LYOPHILISED | 2018 | 2019 |
|--|-------------|-------------|
| Number of AD syringes | 801,700 | |
| Number of re-constitution syringes | 88,200 | |
| Number of safety boxes | 9,800 | |
| Annual Amounts for injection safety devices for Vaccine (US\$) | 41,000 | |
| New Vaccine Support (NVS), Pneumococcal (PCV13), 4 dose(s) per vial, LIQUID,Routine | 2018 | 2019 |
| Number of AD syringes | 1,292,700 | |
| Number of re-constitution syringes | - | |
| Number of safety boxes | 14,225 | |
| Annual Amounts for injection safety devices for Vaccine (US\$) | 59,000 | |
| New Vaccine Support (NVS), DTP-HepB-Hib, 10 dose(s) per vial, LIQUID,Routine | 2018 | 2019 |
| Number of AD syringes | 564,200 | |
| Number of re-constitution syringes | - | |
| Number of safety boxes | 6,225 | |
| Annual Amounts for injection safety devices for Vaccine (US\$) | 26,000 | |
| New Vaccine Support (NVS), HPV Quadrivalent, 1 dose(s) per vial, LIQUID | 2018 | 2019 |
| Number of AD syringes | | 546,400 |
| Number of re-constitution syringes | | |
| Number of safety boxes | | 6,025 |
| Annual Amounts for injection safety devices for Vaccine (US\$) | | 25,000 |

9. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

10. Self-procurement: Not applicable

11. Co-financing obligations:

Co-financing requirements are listed in the relevant vaccine Decision Letter.

Signed by,

Hind Khatib-Othman

On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

12 April 2018